Quick Summary — GUTS scores higher on quality with 4.4/10 vs GPCR's 4.1/10. GPCR trades at $37.19 while GUTS trades at $0.79. Both analyzed daily using SEC EDGAR data across 13 institutional models.
GUTS scores higher with a 4.4/10 quality rating vs GPCR's 4.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.
At $37.19, GPCR trades +64.5% above its Bayesian DCF fair value of $13.21, while GUTS at $0.79 trades +67.1% above its estimate of $0.26. GUTS shows a wider gap between price and intrinsic value.
GPCR earns a Quality of Company score of 4.1/10 compared to GUTS's 4.4/10. The scores are closely matched, indicating similar fundamental quality profiles. The QOC score synthesizes 32 signals spanning profitability margins, revenue growth, free cash flow, capital allocation, and leverage.
GPCR carries a SAFE value trap risk (18/100) while GUTS shows SAFE risk (20/100). Both companies show manageable value trap risk, suggesting their current valuations are not artificially depressed by fundamental deterioration.
Both GPCR and GUTS operate in Biotechnology, which has 566 stocks tracked by CirclFi. Same-industry comparisons provide the most direct insight into relative valuation since both companies face similar regulatory environments, market dynamics, and competitive pressures. Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN), and ensemble methods (CUCE).
11 hidden models compare GPCR vs GUTS differently — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more. Some may disagree with the 2 you see above.
Bloomberg Terminal: ~$2,000/mo · FactSet: ~$1,000/mo · CirclFi: $0.90/day
See All 13 Models — $0.90/dayWe don’t predict prices. We show you what 13 independent mathematical frameworks say a stock is worth — and let you decide.